China Biologic Products Holdings (China Biologic Products Holdings) Interest Coverage : 658.43 (As of Sep. 2020)

View and export this data going back to 2001. Start your Free Trial

What is China Biologic Products Holdings Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. China Biologic Products Holdings's Operating Income for the three months ended in Sep. 2020 was $52.0 Mil. China Biologic Products Holdings's Interest Expense for the three months ended in Sep. 2020 was $-0.1 Mil. China Biologic Products Holdings's interest coverage for the quarter that ended in Sep. 2020 was 658.43. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

China Biologic Products Holdings Inc has no debt.

The historical rank and industry rank for China Biologic Products Holdings's Interest Coverage or its related term are showing as below:

CBPO' s Interest Coverage Range Over the Past 10 Years
Min: 12.2 Med: 76.68 Max: 566.59
Current: 363.38

CBPO's Interest Coverage is not ranked
in the Biotechnology industry.
Industry Median: 134.49 vs CBPO: 363.38

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

China Biologic Products Holdings Interest Coverage Historical Data

The historical data trend for China Biologic Products Holdings's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

China Biologic Products Holdings Interest Coverage Chart

China Biologic Products Holdings Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Interest Coverage

Get a 7-Day Free Trial

76.77

566.59

233.03

432.46

293.28

China Biologic Products Holdings Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Interest Coverage	Get a 7-Day Free Trial															417.28	77.16	647.86	576.92	658.43

Competitive Comparison of China Biologic Products Holdings's Interest Coverage

For the Biotechnology subindustry, China Biologic Products Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Biologic Products Holdings's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Biologic Products Holdings's Interest Coverage distribution charts can be found below:

* The bar in red indicates where China Biologic Products Holdings's Interest Coverage falls into.

China Biologic Products Holdings Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

China Biologic Products Holdings's Interest Coverage for the fiscal year that ended in Dec. 2019 is calculated as

Here, for the fiscal year that ended in Dec. 2019, China Biologic Products Holdings's Interest Expense was $-0.6 Mil. Its Operating Income was $163.6 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.0 Mil.

Interest Coverage	=	-1	*	Operating Income (A: Dec. 2019 )	/	Interest Expense (A: Dec. 2019 )
	=	-1	*	163.648	/	-0.558
	=	293.28

China Biologic Products Holdings's Interest Coverage for the quarter that ended in Sep. 2020 is calculated as

Here, for the three months ended in Sep. 2020, China Biologic Products Holdings's Interest Expense was $-0.1 Mil. Its Operating Income was $52.0 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.0 Mil.

Interest Coverage	=	-1	*	Operating Income (Q: Sep. 2020 )	/	Interest Expense (Q: Sep. 2020 )
	=	-1	*	52.016	/	-0.079
	=	658.43

The higher the ratio, the stronger the company's Financial Strength is.

China Biologic Products Holdings (NAS:CBPO) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

China Biologic Products Holdings Interest Coverage Related Terms

Thank you for viewing the detailed overview of China Biologic Products Holdings's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

China Biologic Products Holdings (China Biologic Products Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Biologic Products Holdings Inc (NAS:CBPO) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Chaoyang Park Road, 18th Floor, Jialong International Building, Chaoyang District, Beijing, CHN, 100125

Website

http://www.chinabiologic.com

China Biologic Products Holdings Inc is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.

Executives

Zhijing Cbpo Liu	officer: Corporate Vice President	19 CHAOYANG PARK ROAD 18/F, JIALONG INTERNATIONAL BUILDING BEIJING F4 100125
Sean Shao	director	21ST FLOOR, EVERBRIGHT BANK BUILDING, ZHUZILIN, FUTIAN DISTRICT, SHENZHEN, GUANGDONG F4 518040
David Gao	director, officer: Chief Executive Officer	C/ BEIJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Albert Yeung	director	C/O BEIJING MED-PHARM CORPORATION 600 WEST GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
David Hui Li	director	C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017
Min Fang	director	UNIT 2206, BUND CENTER OFFICE TOWER NO. 222 YANAN ROAD (EAST) SHANGHAI F4 200002
Zhijun Tong	director	C/O BMP SUNSTONE CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Joseph Chow	director	10110 SORRENTO VALLEY ROAD SUITE C SAN DIEGO CA 92121
Yungang Lu	director	4TH FLOOR, ZHONGDIAN INFORMATION TOWER 6 ZHONGGUANCUN S. ST., HAIDIAN DIST. BEIJING F4 100086
Warburg Pincus Llc	10 percent owner	450 LEXINGTON AVENUE, NEW YORK NY 10017
Wp X Biologics Llc	director, 10 percent owner	C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK X1 10017
Warburg Pincus X Partners, L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus Private Equity X, L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X Gp L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X, L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017